Eoneren/E+ via Getty Images Short interest for healthcare stocks in S&P 500 increased during September end vs.

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget. Even after its sell ...

Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker. According to S&P ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Moderna's stock has fallen due to the weak management revenue guidance, but I remain positive about its long-term potential. Key developments include the next-gen COVID-19 vaccine, the RSV vaccine ...

The PCMPA has slammed Moderna over an unapproved WhatsApp message that offered children in the U.K. 1,500 pounds sterling ($2,000) to participate in a clinical trial of its COVID-19 booster vaccine.

Moderna's updated COVID-19 vaccine was approved by Health Canada. The updated vaccine targets the KP.2 variant. Moderna, Inc. MRNA shares are moving higher on Tuesday after the company announced ...

Although COVID-19 has been somewhat controlled, it is still present in forms of different strains, which is why Pfizer, Moderna and Novavax have introduced a new vaccine shot to the public to keep up ...

On Tuesday, Health Canada announced it had approved Moderna’s latest COVID vaccine that’s been reformulated to target prevalent variants like KP.2. The updated formula will be available to ...

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.